Insider buying is never a guarantee that the stock price will advance; it is a reliable signal that the stock has value and a high potential to advance.
Insiders Buy CalciMedica: Primary Candidate Advancing Through Trials
CalciMedica insiders are taking advantage of the stock's low price. The group, including the CEO, chairman, and other board members, has been buying the stock since it IPOd and own a considerable amount of the shares. Total insider ownership including large shareholders, private equity, and venture capital is over 40%; the company’s executives control a little more than 10%. Institutions, which own another 15% of the stock, are also buying.
The analysts are optimistic. InsiderTrades.com tracks only four with current reports, but they are bullish, rating the stock as a firm Buy with a price target offering a double-digit upside. The lowest price target issued by a major analyst is $16 or 360% upside, which is good enough.
The consensus price target implies a 460% upside for this market, and the high end adds another few thousand basis points to it. The most significant risk for investors is dilution. The company’s stock count doubled in the last year, and a new offering is on the table. The company’s balance sheet is OK, but losses continue to mount as the trials and development pipeline advance.
BKV Corporation: Net-Zero Natural Gas Operations by 2030
Among the catalysts for this market are growth and earnings. The company’s first report was lackluster with start-up costs and investments offsetting revenue and cash flow, but things will change soon. The analysts forecast a 25% top-line advance and profitability in 2025.
The article "Insiders Bet Big on These Small Cap Stocks" first appeared on MarketBeat.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
